Premysl Bercik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Premysl Bercik has a total of 312 co-authors. Here are the top co-authors by number of shared publications:
- Elena Francisca Verdu
Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada
27 shared publications Jun Lu
Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University
21 shared publicationsStephen M. Collins
Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
19 shared publications- Stephen Michael Collins
Department of Medicine, The Farncombe Family Digestive Health Research Institute, Faculty of Health Sciences, McMaster University
19 shared publications - Giada De Palma
Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada
18 shared publications - Maria Ines Pinto-Sanchez
Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
12 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1)
Towards optimizing the host response to biotics: a report of an International Scientific Association for Probiotics and Prebiotics working group
The International Scientific Association for Probiotics and Prebiotics (ISAPP) annual meeting held July 15–17, 2025, in Banff, Canada, included discussion groups of invited experts bringing diverse...
- 8 September 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1)
Open AccessTowards optimizing the host response to biotics: a report of an International Scientific Association for Probiotics and Prebiotics working group
The International Scientific Association for Probiotics and Prebiotics (ISAPP) annual meeting held July 15–17, 2025, in Banff, Canada, included discussion groups of invited experts bringing diverse...
- 8 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (857) , eadz4589
Phage intervention improves colitis and response to corticosteroids by attenuating virulence of Crohn’s disease–associated bacteria
Adherent-invasive Escherichia coli (AIEC) exhibits proinflammatory properties and has been implicated in the pathogenesis of Crohn’s disease (CD), a form of inflammatory bowel disease (IBD). Antibiotic use in CD lacks specificity and may worsen microbiome disruption, prompting interest in bacteriophages (phages) for targeted microbiome editing. Here, we identified HER259, a phage active against clinical AIEC isolates. HER259 ameliorated colitis in gnotobiotic models and attenuated the virulence of AIEC strain NRG857c, including suppression of the FimH adhesin through inversion of the fimS promoter to its “off” orientation. The effects were confirmed in CD-microbiota colitis models. Withdrawal of HER259 treatment led to reversion of the fimS promoter and reactivated colitis. The HER259 phage also enhanced the therapeutic effect of subtherapeutic budesonide independent of microbial drug metabolism. These findings support targeted phage therapy as an adjunct treatment approach in IBD, demonstrating modulation of bacterial virulence and improved response to conventional treatments that may reduce drug-related side effects.
- 8 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (857) , eadz4589
Phage intervention improves colitis and response to corticosteroids by attenuating virulence of Crohn’s disease–associated bacteria
Adherent-invasive Escherichia coli (AIEC) exhibits proinflammatory properties and has been implicated in the pathogenesis of Crohn’s disease (CD), a form of inflammatory bowel disease (IBD). Antibiotic use in CD lacks specificity and may worsen microbiome disruption, prompting interest in bacteriophages (phages) for targeted microbiome editing. Here, we identified HER259, a phage active against clinical AIEC isolates. HER259 ameliorated colitis in gnotobiotic models and attenuated the virulence of AIEC strain NRG857c, including suppression of the FimH adhesin through inversion of the fimS promoter to its “off” orientation. The effects were confirmed in CD-microbiota colitis models. Withdrawal of HER259 treatment led to reversion of the fimS promoter and reactivated colitis. The HER259 phage also enhanced the therapeutic effect of subtherapeutic budesonide independent of microbial drug metabolism. These findings support targeted phage therapy as an adjunct treatment approach in IBD, demonstrating modulation of bacterial virulence and improved response to conventional treatments that may reduce drug-related side effects.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1) , 2664640
Saccharomyces boulardii CNCM I-745 synergizes with the small intestinal microbiota to boost AhR signaling in celiac disease
Celiac disease (CeD) is an immune-mediated condition that leads to small intestinal villous atrophy and is driven by dietary gluten in individuals carrying HLA-DQ2 and DQ8. Microbial factors have been implicated in both the onset of CeD and persistent symptoms (non-responsive CeD) after the gluten-free diet (GFD), through mechanisms including impaired tryptophan metabolism and aryl hydrocarbon receptor (AhR) pathway activation. Although probiotics have been shown to be safe in CeD, there are currently no clinical recommendations for strains that target disease-related mechanisms. We here demonstrate that S. boulardii activated the AhR pathway in gluten-sensitized mice expressing HLA-DQ8, improving gluten-immunopathology. Mechanistically, S. boulardii enhanced the CeD patients' microbiota capacity for AhR activation when duodenal indole-producing commensals, such as Lactobacillus reuteri, were present. Our study provides preclinical evidence that S. boulardii CNCM I-745 targets a microbial deficiency previously described in CeD through modulation of microbial tryptophan metabolism. The findings encourage clinical testing of S. boulardii in CeD to prevent or better treat non-responsive cases.
- 1 May 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1) , 2664640
Open AccessSaccharomyces boulardii CNCM I-745 synergizes with the small intestinal microbiota to boost AhR signaling in celiac disease
Celiac disease (CeD) is an immune-mediated condition that leads to small intestinal villous atrophy and is driven by dietary gluten in individuals carrying HLA-DQ2 and DQ8. Microbial factors have been implicated in both the onset of CeD and persistent symptoms (non-responsive CeD) after the gluten-free diet (GFD), through mechanisms including impaired tryptophan metabolism and aryl hydrocarbon receptor (AhR) pathway activation. Although probiotics have been shown to be safe in CeD, there are currently no clinical recommendations for strains that target disease-related mechanisms. We here demonstrate that S. boulardii activated the AhR pathway in gluten-sensitized mice expressing HLA-DQ8, improving gluten-immunopathology. Mechanistically, S. boulardii enhanced the CeD patients' microbiota capacity for AhR activation when duodenal indole-producing commensals, such as Lactobacillus reuteri, were present. Our study provides preclinical evidence that S. boulardii CNCM I-745 targets a microbial deficiency previously described in CeD through modulation of microbial tryptophan metabolism. The findings encourage clinical testing of S. boulardii in CeD to prevent or better treat non-responsive cases.
- Top Cited PapersOpen Access
- 31 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Small intestinal microbial fiber metabolism dysfunction in celiac disease
Celiac disease (CeD) is an immune-mediated condition driven by dietary gluten resulting in small intestinal mucosal inflammation and injury, along with myriads of symptoms. The only treatment is a lifelong gluten-free diet (GFD) and although most patients improve, the restriction can lead to nutrient deficiencies including fiber. Duodenal microbiota is known to be altered in CeD, but whether and how the microbial fiber metabolism may be affected is unknown. Here we show that CeD patients had impaired microbial fiber metabolism in the small intestine which associated with depletion of the fiber degrading taxa, Prevotella spp, independent of treatment with the GFD. Colonization of germ-free mice with Prevotella spp increased small intestinal short chain fatty acids (SCFA). In gluten-sensitized mice expressing the celiac risk gene, HLA-DQ8, an inulin-supplemented diet facilitated microbial saccharolytic function and SCFA production to accelerate mucosal healing in the small intestine during the GFD. The results support clinical investigations of dietary fiber supplementation and microbial fiber degradation to enhance responses to the GFD in CeD.
- 31 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessSmall intestinal microbial fiber metabolism dysfunction in celiac disease
Celiac disease (CeD) is an immune-mediated condition driven by dietary gluten resulting in small intestinal mucosal inflammation and injury, along with myriads of symptoms. The only treatment is a lifelong gluten-free diet (GFD) and although most patients improve, the restriction can lead to nutrient deficiencies including fiber. Duodenal microbiota is known to be altered in CeD, but whether and how the microbial fiber metabolism may be affected is unknown. Here we show that CeD patients had impaired microbial fiber metabolism in the small intestine which associated with depletion of the fiber degrading taxa, Prevotella spp, independent of treatment with the GFD. Colonization of germ-free mice with Prevotella spp increased small intestinal short chain fatty acids (SCFA). In gluten-sensitized mice expressing the celiac risk gene, HLA-DQ8, an inulin-supplemented diet facilitated microbial saccharolytic function and SCFA production to accelerate mucosal healing in the small intestine during the GFD. The results support clinical investigations of dietary fiber supplementation and microbial fiber degradation to enhance responses to the GFD in CeD.
- Open Access
- 7 January 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1) , 2610597
The role of gut microbiota in chronic intestinal pseudo-obstruction: exploring fecal microbiota transplantation as a treatment option
Chronic intestinal pseudo-obstruction (CIPO) is characterized by bowel dilation and obstructive symptoms without any structural blockage. Although the microbiota is known to affect gastrointestinal function, its role in CIPO is poorly understood. We aimed to characterize the CIPO microbiota, investigate its role in disease expression and explore the therapeutic role of fecal microbiota transplantation (FMT). CIPO patients (n = 14) and healthy controls (HC, n = 12) were recruited from Italy and Canada. Microbiota profiles and functions were assessed by 16S rRNA sequencing and PICRUSt. Germ-free NIH Swiss mice were colonized with HC and CIPO microbiota, their intestinal transit and bowel distension were assessed by videofluoroscopy and computed tomography (CT), and the expression of host genes by NanoString®. The CIPO microbiota exhibited reduced microbial diversity with dominance of Proteobacteria and altered metabolic function. Mice with CIPO microbiota developed marked bowel distension and slow intestinal transit associated with altered expression of multiple genes related to immunity, the intestinal barrier and neuromuscular function. FMT from a HC improved the microbiota profile, intestinal transit and bowel distension in both CIPO mice and a selected CIPO patient, in whom a marked clinical improvement was sustained for 8 y. Thus, our findings support the use of microbiota-directed therapies to induce clinical improvement in CIPO patients.
- 7 January 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1) , 2610597
Open AccessThe role of gut microbiota in chronic intestinal pseudo-obstruction: exploring fecal microbiota transplantation as a treatment option
Chronic intestinal pseudo-obstruction (CIPO) is characterized by bowel dilation and obstructive symptoms without any structural blockage. Although the microbiota is known to affect gastrointestinal function, its role in CIPO is poorly understood. We aimed to characterize the CIPO microbiota, investigate its role in disease expression and explore the therapeutic role of fecal microbiota transplantation (FMT). CIPO patients (n = 14) and healthy controls (HC, n = 12) were recruited from Italy and Canada. Microbiota profiles and functions were assessed by 16S rRNA sequencing and PICRUSt. Germ-free NIH Swiss mice were colonized with HC and CIPO microbiota, their intestinal transit and bowel distension were assessed by videofluoroscopy and computed tomography (CT), and the expression of host genes by NanoString®. The CIPO microbiota exhibited reduced microbial diversity with dominance of Proteobacteria and altered metabolic function. Mice with CIPO microbiota developed marked bowel distension and slow intestinal transit associated with altered expression of multiple genes related to immunity, the intestinal barrier and neuromuscular function. FMT from a HC improved the microbiota profile, intestinal transit and bowel distension in both CIPO mice and a selected CIPO patient, in whom a marked clinical improvement was sustained for 8 y. Thus, our findings support the use of microbiota-directed therapies to induce clinical improvement in CIPO patients.
- Open Access
Altered microbial carbohydrate metabolism is associated with anxiety and gastrointestinal symptoms in patients with Generalized Anxiety Disorder
Background: Generalized anxiety disorder (GAD) is a common psychiatric condition, with unknown etiology and pathophysiology. Recent studies have suggested alterations in the microbiota-gut-brain axis may be involved in the development of GAD. We aimed to explore the interactions between the gut microbiota, gastrointestinal and psychiatric symptoms, neuroimmune markers and dietary patterns in patients with GAD. Methods: We recruited 83 GAD patients and 98 age- and sex-matched healthy controls (HC) and assessed their psychiatric and gastrointestinal symptoms, and long-term diet using validated questionnaires. We measured serum and stool neuroimmune markers and metabolites by ELISA and LC-MS, microbiota was analyzed using 16S rRNA gene sequencing with functional predictions by PICRUSt2. Microbial carbohydrate degradation capacity was assessed ex vivo . The data was analyzed using classical statistics and machine learning (XGBoost). Results: GAD patients exhibited higher BMI, gastrointestinal symptoms and inflammatory markers, while reporting reduced intake of fiber and other macro- and micronutrients compared to HC. Gastrointestinal symptoms were the most predictive feature separating GAD from HC. GAD patients had a distinct microbiota profile, dominated by Bacteroides , compared with a Prevotella -dominated microbiota in HC. Carbohydrate degradation pathways were enriched in GAD and strongly associated with Bacteroides abundance. Anxiety scores correlated with Bacteroides abundance, carbohydrate degradation pathways and gastrointestinal symptoms, while negatively correlating with dietary fiber intake. Ex vivo mucin-to-inulin degradation ratio was higher in GAD and correlated with inflammatory markers. Conclusions: GAD patients exhibited marked gastrointestinal symptoms, elevated immune markers, reduced fiber intake and a Bacteroides -dominated microbiota that preferentially degrades mucin. These data suggest that their microbiota adapted to utilize host-derived carbohydrates that may affect the mucus barrier, altering immune homeostasis and leading to gastrointestinal symptoms and anxiety. Dietary interventions, such as gradually increasing fiber intake, could reprogram bacterial carbohydrate metabolism, thus ameliorating gut barrier function and alleviating anxiety and gastrointestinal symptoms.
Open AccessAltered microbial carbohydrate metabolism is associated with anxiety and gastrointestinal symptoms in patients with Generalized Anxiety Disorder
Background: Generalized anxiety disorder (GAD) is a common psychiatric condition, with unknown etiology and pathophysiology. Recent studies have suggested alterations in the microbiota-gut-brain axis may be involved in the development of GAD. We aimed to explore the interactions between the gut microbiota, gastrointestinal and psychiatric symptoms, neuroimmune markers and dietary patterns in patients with GAD. Methods: We recruited 83 GAD patients and 98 age- and sex-matched healthy controls (HC) and assessed their psychiatric and gastrointestinal symptoms, and long-term diet using validated questionnaires. We measured serum and stool neuroimmune markers and metabolites by ELISA and LC-MS, microbiota was analyzed using 16S rRNA gene sequencing with functional predictions by PICRUSt2. Microbial carbohydrate degradation capacity was assessed ex vivo . The data was analyzed using classical statistics and machine learning (XGBoost). Results: GAD patients exhibited higher BMI, gastrointestinal symptoms and inflammatory markers, while reporting reduced intake of fiber and other macro- and micronutrients compared to HC. Gastrointestinal symptoms were the most predictive feature separating GAD from HC. GAD patients had a distinct microbiota profile, dominated by Bacteroides , compared with a Prevotella -dominated microbiota in HC. Carbohydrate degradation pathways were enriched in GAD and strongly associated with Bacteroides abundance. Anxiety scores correlated with Bacteroides abundance, carbohydrate degradation pathways and gastrointestinal symptoms, while negatively correlating with dietary fiber intake. Ex vivo mucin-to-inulin degradation ratio was higher in GAD and correlated with inflammatory markers. Conclusions: GAD patients exhibited marked gastrointestinal symptoms, elevated immune markers, reduced fiber intake and a Bacteroides -dominated microbiota that preferentially degrades mucin. These data suggest that their microbiota adapted to utilize host-derived carbohydrates that may affect the mucus barrier, altering immune homeostasis and leading to gastrointestinal symptoms and anxiety. Dietary interventions, such as gradually increasing fiber intake, could reprogram bacterial carbohydrate metabolism, thus ameliorating gut barrier function and alleviating anxiety and gastrointestinal symptoms.
- Open Access
- 12 May 2025
- Published by Springer Nature in Research Square
Small intestinal microbial fiber metabolism dysfunction in celiac disease
Celiac disease (CeD) is an immune-mediated condition driven by dietary gluten resulting in small intestinal mucosal inflammation and injury, along with myriads of symptoms. The only treatment is a lifelong gluten-free diet (GFD) and although most patients improve, the restriction can lead to nutrient deficiencies including fiber. While duodenal microbiota is altered in CeD, its fiber metabolic capacity is unknown. Here we show that both active and GFD-treated CeD patients had impaired microbial fiber metabolism in the small intestine which associates with depletion of the carbolytic taxa Prevotella spp. Colonization of germ-free mice with Prevotella spp increased small intestinal short chain fatty acids (SCFA). In gluten-sensitized mice expressing the celiac risk gene, HLA-DQ8, an inulin-supplemented diet facilitated microbial carbolytic function, SCFAs production and accelerated mucosal healing in the small intestine during GFD. The results support clinical investigations of dietary fiber supplementation and microbial carbolytic function to enhance responses to GFD in CeD.
- 12 May 2025
- Published by Springer Nature in Research Square
Open AccessSmall intestinal microbial fiber metabolism dysfunction in celiac disease
Celiac disease (CeD) is an immune-mediated condition driven by dietary gluten resulting in small intestinal mucosal inflammation and injury, along with myriads of symptoms. The only treatment is a lifelong gluten-free diet (GFD) and although most patients improve, the restriction can lead to nutrient deficiencies including fiber. While duodenal microbiota is altered in CeD, its fiber metabolic capacity is unknown. Here we show that both active and GFD-treated CeD patients had impaired microbial fiber metabolism in the small intestine which associates with depletion of the carbolytic taxa Prevotella spp. Colonization of germ-free mice with Prevotella spp increased small intestinal short chain fatty acids (SCFA). In gluten-sensitized mice expressing the celiac risk gene, HLA-DQ8, an inulin-supplemented diet facilitated microbial carbolytic function, SCFAs production and accelerated mucosal healing in the small intestine during GFD. The results support clinical investigations of dietary fiber supplementation and microbial carbolytic function to enhance responses to GFD in CeD.
- Open Access
- 9 March 2025
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 127, 238-250
Innate immune system signaling and intestinal dendritic cells migration to the brain underlie behavioral changes after microbial colonization in adult mice
- 9 March 2025
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 127, 238-250
Open AccessInnate immune system signaling and intestinal dendritic cells migration to the brain underlie behavioral changes after microbial colonization in adult mice
- Open Access
Innate immune system signaling and CD11b + CD11c + CD103 + cell migration to the brain underlie changes in mouse behavior after microbial colonization
Background and Aims: Accumulating evidence suggests the microbiota is a key factor in disorders of gut-brain interaction (DGBI), by affecting host immune and neural systems. However, the underlying mechanisms remain elusive due to their complexity and clinical heterogeneity of patients with DGBIs. We aimed to identify neuroimmune pathways that are critical in microbiota-gut-brain communication during de novo gut colonization. Methods: We employed a combination of gnotobiotic and state-of-the-art microbial tools, behavioral analysis, immune and pharmacological approaches. Germ-free wild type, MyD88 −/− Ticam1 −/− and SCID mice were studied before and after colonization with specific pathogen-free microbiota, Altered Schaedler Flora, E. coli or S. typhimurium (permanent or transient colonizers). TLR agonists and antagonists, CCR7 antagonist or immunomodulators were used to study immune pathways. We assessed brain c-Fos, brain-derived neurotrophic factor, and dendritic and glial cells by immunofluorescence, expression of neuroimmune genes by NanoString and performed brain proteomics. Results: Bacterial monocolonization, conventionalization or administration of microbial products to germ-free mice altered mouse behavior similarly, acting through Toll-like receptor or nucleotide-binding oligomerization domain signaling. The process required CD11b + CD11c + CD103 + cell activation and migration into the brain. The change in behavior did not require the continued presence of bacteria and was associated with activation of multiple neuro-immune networks in the gut and the brain. Conclusions: Changes in neural plasticity occur rapidly upon initial gut microbial colonization and involve innate immune signaling to the brain, mediated by CD11b + CD11c + CD103 + cell migration. The results identify a new target with therapeutic potential for DGBIs developing in context of increased gut and blood-brain barrier permeability. Highlights: Microbiota impairment is a key factor in disorders of gut-brain interaction (DGBI) Microbial colonization induces changes in brain and behavior via innate immunity Microbial colonization activates multiple neuro-immune networks in gut and brain Behavioral change is mediated by CD11b + CD11c + CD103 + cells migration to the brain
Open AccessInnate immune system signaling and CD11b + CD11c + CD103 + cell migration to the brain underlie changes in mouse behavior after microbial colonization
Background and Aims: Accumulating evidence suggests the microbiota is a key factor in disorders of gut-brain interaction (DGBI), by affecting host immune and neural systems. However, the underlying mechanisms remain elusive due to their complexity and clinical heterogeneity of patients with DGBIs. We aimed to identify neuroimmune pathways that are critical in microbiota-gut-brain communication during de novo gut colonization. Methods: We employed a combination of gnotobiotic and state-of-the-art microbial tools, behavioral analysis, immune and pharmacological approaches. Germ-free wild type, MyD88 −/− Ticam1 −/− and SCID mice were studied before and after colonization with specific pathogen-free microbiota, Altered Schaedler Flora, E. coli or S. typhimurium (permanent or transient colonizers). TLR agonists and antagonists, CCR7 antagonist or immunomodulators were used to study immune pathways. We assessed brain c-Fos, brain-derived neurotrophic factor, and dendritic and glial cells by immunofluorescence, expression of neuroimmune genes by NanoString and performed brain proteomics. Results: Bacterial monocolonization, conventionalization or administration of microbial products to germ-free mice altered mouse behavior similarly, acting through Toll-like receptor or nucleotide-binding oligomerization domain signaling. The process required CD11b + CD11c + CD103 + cell activation and migration into the brain. The change in behavior did not require the continued presence of bacteria and was associated with activation of multiple neuro-immune networks in the gut and the brain. Conclusions: Changes in neural plasticity occur rapidly upon initial gut microbial colonization and involve innate immune signaling to the brain, mediated by CD11b + CD11c + CD103 + cell migration. The results identify a new target with therapeutic potential for DGBIs developing in context of increased gut and blood-brain barrier permeability. Highlights: Microbiota impairment is a key factor in disorders of gut-brain interaction (DGBI) Microbial colonization induces changes in brain and behavior via innate immunity Microbial colonization activates multiple neuro-immune networks in gut and brain Behavioral change is mediated by CD11b + CD11c + CD103 + cells migration to the brain